Serotonin Control of Impulsivity in Tourette Disorder

Last updated: December 2, 2024
Sponsor: Hospices Civils de Lyon
Overall Status: Active - Recruiting

Phase

2

Condition

Tourette's Syndrome

Tic Disorders

Autism

Treatment

Administration of a PET radiotracer

Clinical Study ID

NCT05942716
69HCL22_0683
  • Ages 18-65
  • All Genders

Study Summary

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer ([18F]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

Eligibility Criteria

Inclusion

  • Inclusion Criteria * :

  • Male or Female

  • Diagnosed with a Tourette Disorder following the DSM-5

  • Age between 18-65 years

  • Member of a social security scheme in France

  • Freely-given informed consent to participate to this study (written form)

  • With a current treatment by aripiprazole already scheduled

  • With Tics compatible with TEP/fMRI exams

  • Having (for women only) effective contraception throughout participation in the study.

Exclusion Criteria * :

  • Male or Female

  • A serious not controlled psychiatric comorbidity

  • A serious, evolving or debilitating pathology with a potential influence on the study

  • Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)

  • Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)

  • Women breastfeeding

  • Protected or restricted person (administratively or in judicial terms)

  • Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study

  • Do not speak french

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Administration of a PET radiotracer
Phase: 2
Study Start date:
September 24, 2024
Estimated Completion Date:
September 24, 2028

Connect with a study center

  • Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon

    Bron, 69677
    France

    Active - Recruiting

  • Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière

    Paris, 75013
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.